The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken.
Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.
FDA developing guidelines for oncology endpoints.
Also in this 8-page issue: NIH Conflict of Interest panel recommends that NIH employees should not receive stock options or equities as compensation for outside work.
Michelle Le Beau named director of University of Chicago Cancer Research Center.
Funding opportunities listed.
Trending Stories
- As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - Cedars-Sinai spearheads first national certification program for COE staff at cancer centers
- Menin inhibitors emerge as new treatment for advanced AML
- Trump 2016: A look back at the 45th president’s impact on oncology
- Patient navigation benefits health systems, improves care
Initial data presented at the White House come a year after CMS payment began - Larry Einhorn reflects on his pioneering work on platinum-based chemotherapy at the AACI/CCAF annual meeting
